Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Ivar S, Jensen"'
Autor:
Joanne M Hathway, Lesley-Ann Miller-Wilson, Abhishek Sharma, Ivar S Jensen, Weiyu Yao, Sajjad Raza, Philip D Parks, Milton C Weinstein
Publikováno v:
Journal of Market Access & Health Policy, Vol 9, Iss 1 (2021)
Background: In the United States (US), colorectal cancer (CRC) is the second leading cause of cancer-related deaths. With the majority of the US population covered by employer-based health plans, employers can play a critical role in increasing CRC s
Externí odkaz:
https://doaj.org/article/c095f2e435d34febb0188449d95dbad8
Publikováno v:
Journal of Market Access & Health Policy, Vol 8, Iss 1 (2020)
Background: Current detection methodologies are often unable to identify the location and extent of recurrent prostate cancer (PCa) leading potentially to ‘futile’ local therapies in the presence of metastatic disease. The use of 18 F-fluciclovin
Externí odkaz:
https://doaj.org/article/bf1d2a292dcb4edbb8d1e4e2fcb9cd2c
Publikováno v:
Drugs in Context, Pp 1-14 (2016)
Background: Although a number of monoimmunotherapies and targeted therapies are available to treat BRAF+ advanced melanoma, response rates remain relatively low in the range of 22–53% with progression-free survival (PFS) in the range of 4.8–8.8 m
Externí odkaz:
https://doaj.org/article/ed0cccff9bed421392946efa58855a26
Autor:
Gregg W. Stone, Charles Michael Gibson, Philippe Gabriel Steg, Ivar S Jensen, Khalid Salahuddin, Marc Claussen, Jayne Prats, Deepak L. Bhatt, Elizabeth Wu, Kenneth W. Mahaffey, Philip L. Cyr, Thomas Winkler
Publikováno v:
American Journal of Cardiovascular Drugs
Objectives The objective of this study was to evaluate a US hospital’s cost implications and outcomes of cangrelor use in percutaneous coronary intervention (PCI) patients with two or more angiographic high-risk features (HRFs), including avoidance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3da7c241f5fabde9d95a531d7f24062
https://doi.org/10.1007/s40256-021-00491-9
https://doi.org/10.1007/s40256-021-00491-9
Autor:
Milton C. Weinstein, Sajjad Raza, Weiyu Yao, Ivar S Jensen, Abhishek Sharma, Joanne M Hathway, Lesley-Ann Miller-Wilson, Philip D. Parks
Publikováno v:
Journal of Market Access & Health Policy, Vol 9, Iss 1 (2021)
Journal of Market Access & Health Policy
article-version (VoR) Version of Record
Journal of Market Access & Health Policy
article-version (VoR) Version of Record
Background: In the United States (US), colorectal cancer (CRC) is the second leading cause of cancer-related deaths. With the majority of the US population covered by employer-based health plans, employers can play a critical role in increasing CRC s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d059aeaf1ee3fb297dd1388fda35240
https://doi.org/10.1080/20016689.2021.1948670
https://doi.org/10.1080/20016689.2021.1948670
Autor:
Joanne M Hathway, Milton C. Weinstein, Ivar S Jensen, Catherine Regan, Philip D. Parks, Anupam B. Jena, Lesley-Ann Miller-Wilson, A. Burak Ozbay
Aims: To evaluate total costs and health consequences of a colorectal cancer (CRC) screening program with colonoscopy, fecal immunochemical tests (FIT), and expanded use of multitarget stool DNA (mt-sDNA) from the perspectives of Integrated Delivery
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e7d1d39b66352e4d3826955ac93346e
Autor:
Joanne M Hathway, Weiyu Yao, Milton C. Weinstein, Ivar S Jensen, Philip D. Parks, Lesley-Ann Miller-Wilson
To examine the impact of increasing multi-target stool DNA test (mt-sDNA [Cologuard]) utilization for colorectal cancer (CRC) screening in cohorts aged 50–75 and 45–75 years old with varying levels of adherence from the perspectives of integrated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49feb88693b0bf806d7e81c9078bed93
Publikováno v:
Journal of Market Access & Health Policy, Vol 8, Iss 1 (2020)
Background: Current detection methodologies are often unable to identify the location and extent of recurrent prostate cancer (PCa) leading potentially to ‘futile’ local therapies in the presence of metastatic disease. The use of 18 F-fluciclovin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c192a13b74e3c61015f067322f58f16
https://doaj.org/article/bf1d2a292dcb4edbb8d1e4e2fcb9cd2c
https://doaj.org/article/bf1d2a292dcb4edbb8d1e4e2fcb9cd2c
Publikováno v:
Value in Health. 24:S16
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::576a583b5e94b02222e8296e01e4dba1
https://doi.org/10.1016/j.jval.2021.04.082
https://doi.org/10.1016/j.jval.2021.04.082
Publikováno v:
Journal of Market Access & Health Policy
Background: Current detection methodologies are often unable to identify the location and extent of recurrent prostate cancer (PCa) leading potentially to ‘futile’ local therapies in the presence of metastatic disease. The use of 18 F-fluciclovin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::28d0298e9edc4e7b50c9b830d95c3332
https://pubmed.ncbi.nlm.nih.gov/32341772
https://pubmed.ncbi.nlm.nih.gov/32341772